ADAMS LABS WILL MARKET NEW PRESCRIPTION ANTIHISTAMINE SEMPREX-D
This article was originally published in The Tan Sheet
ADAMS LABS WILL MARKET NEW PRESCRIPTION ANTIHISTAMINE SEMPREX-D beginning this month under a license agreement with Burroughs Wellcome, which developed the drug. Semprex-D (acrivastine 8 mg/pseudoephedrine 60 mg) was approved by FDA on March 25 for seasonal allergic rhinitis. The antihistamine/decongestant product received a "1,4S" rating from FDA, indicating a new molecular entity combination given a standard review. The NDA (19-806) was submitted in December 1987.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC